Literature DB >> 10639323

Patterned entry and egress by Epstein-Barr virus in polarized CR2-positive epithelial cells.

J Chodosh1, Y j Gan, V P Holder, J W Sixbey.   

Abstract

In polarized epithelium direction of viral entry and release correlates with proclivity of a virus to establish local versus systemic infection. The Epstein-Barr virus (EBV), whose principal tissue reservoir is B lymphocytes, also has disease manifestations in epithelium, suggesting intertissue spread potentially influenced by epithelial cell polarity. We stably transfected the B lymphocyte EBV receptor (CR2/CD21) into Madin-Darby canine kidney (MDCK) epithelial cells used extensively to study effects of cell polarity on infection by both DNA and RNA viruses. CR2/CD21 was detected on both apical and basolateral surfaces of polarized MDCK cells, with predominant expression basolaterally. However, infectivity was up to four-fold greater apically, suggesting that endogenous cell surface molecules, sorted asymmetrically onto polarized plasma membranes, may be involved in EBV entry into MDCK cells. EBV gp350/220, a replicative cycle glycoprotein added to the virus envelope on egress through the cell membrane, was immunolocalized by confocal microscopy to basolateral cell surfaces only. Apical entry of EBV with subsequent basolateral release of newly replicated virus favors systemic infection by viral dissemination to underlying lymphocytic aggregations. Under conditions of long-term culture, latent EBV was not stably maintained in these cells, suggesting that the epithelial phase of acute EBV infection may be transient. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10639323     DOI: 10.1006/viro.1999.0082

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  9 in total

1.  Evidence of an oncogenic gammaherpesvirus in domestic dogs.

Authors:  Shih-Hung Huang; Philip J Kozak; Jessica Kim; Georges Habineza-Ndikuyeze; Charles Meade; Anita Gaurnier-Hausser; Reema Patel; Erle Robertson; Nicola J Mason
Journal:  Virology       Date:  2012-03-08       Impact factor: 3.616

2.  Epstein-Barr virus transcytosis through polarized oral epithelial cells.

Authors:  Sharof M Tugizov; Rossana Herrera; Joel M Palefsky
Journal:  J Virol       Date:  2013-05-22       Impact factor: 5.103

3.  CD21-mediated entry and stable infection by Epstein-Barr virus in canine and rat cells.

Authors:  L Yang; S Maruo; K Takada
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

4.  Length of Epstein-Barr virus termini as a determinant of epithelial cell clonal emergence.

Authors:  Cary A Moody; Rona S Scott; Tao Su; John W Sixbey
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

5.  A tyrosine-based motif in the cytoplasmic tail of pseudorabies virus glycoprotein B is important for both antibody-induced internalization of viral glycoproteins and efficient cell-to-cell spread.

Authors:  Herman W Favoreel; Geert Van Minnebruggen; Hans J Nauwynck; Lynn W Enquist; Maurice B Pensaert
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

6.  Epstein-Barr virus infection negatively impacts the CXCR4-dependent migration of tonsillar B cells.

Authors:  Barbro Ehlin-Henriksson; Frida Mowafi; George Klein; Anna Nilsson
Journal:  Immunology       Date:  2006-03       Impact factor: 7.397

7.  Tamiflu-resistant but HA-mediated cell-to-cell transmission through apical membranes of cell-associated influenza viruses.

Authors:  Kotaro Mori; Takahiro Haruyama; Kyosuke Nagata
Journal:  PLoS One       Date:  2011-11-30       Impact factor: 3.240

8.  Possible DNA viral factors of human breast cancer.

Authors:  Chun-Ru Hsu; Tsong-Ming Lu; Lengsu William Chin; Chi-Chiang Yang
Journal:  Cancers (Basel)       Date:  2010-04-13       Impact factor: 6.639

Review 9.  Entry of viruses through the epithelial barrier: pathogenic trickery.

Authors:  Morgane Bomsel; Annette Alfsen
Journal:  Nat Rev Mol Cell Biol       Date:  2003-01       Impact factor: 94.444

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.